Accelerate Diagnostics Stock (NASDAQ:AXDX)
Previous Close
$1.84
52W Range
$0.73 - $7.00
50D Avg
$1.60
200D Avg
$1.52
Market Cap
$43.10M
Avg Vol (3M)
$57.62K
Beta
0.61
Div Yield
-
AXDX Company Profile
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.
AXDX Performance
Peer Comparison
Ticker | Company |
---|---|
ANIK | Anika Therapeutics, Inc. |
IRMD | IRadimed Corporation |
OFIX | Orthofix Medical Inc. |
AVNS | Avanos Medical, Inc. |
SGHT | Sight Sciences, Inc. |
ITGR | Integer Holdings Corporation |
LUNG | Pulmonx Corporation |
NPCE | NeuroPace, Inc. |
SRDX | Surmodics, Inc. |
LIVN | LivaNova PLC |
KIDS | OrthoPediatrics Corp. |
OSA | ProSomnus, Inc. Common Stock |
AORT | Artivion, Inc. |
AXGN | AxoGen, Inc. |
CVRX | CVRx, Inc. |
CNMD | CONMED Corporation |